CNR1 and opioid use disorder: The present study shows that the CB1R neutral antagonist AM6527 inhibits cocaine and heroin self-administration as well as reinstatement of drug-seeking behavior, while itself is not rewarding or aversive, suggesting that AM6527 and other neutral CB1R antagonists are superior to rimonabant as new pharmacotherapies for treating cocaine and opioid use disorders.